Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBioXcel Therapeutics Inc

BioXcel Therapeutics Inc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-06T21:15:56.847061Z
Market Cap
31.14M

Momentum Score

…

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.01
Low
8.08
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

BioXcel Therapeutics uses an AI-driven platform to identify and develop therapies in neuroscience and immuno-oncology, and has advanced a sublingual dexmedetomidine product for acute agitation in psychiatric settings. Long-term growth drivers include commercialization and uptake of that product, expansion into additional indications, pipeline clinical progress, and partnering or licensing opportunities that could leverage its AI-enabled discovery approach.

Key investment risks include commercialization and reimbursement execution for its approved product, clinical and regulatory setbacks across pipeline programs, competitive alternatives in acute agitation care, and limited financial resources that may require funding.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.05
Dividend Yield
-
Revenue TTM
0.64M
Revenue Per Share
0.05
Gross Profit TTM
0.48M
Debt / Equity
-1.15
ROE
-1766.94%
Net Debt
81.18M
ROCE
551.66%
Diluted EPS TTM
-5.73

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -69.90M -59.60M -179.05M -165.76M -106.93M
Net income -69.90M -59.60M -179.05M -171.85M -106.63M
Selling general administrative 20.49M 33.10M 63.51M 68.76M 54.23M
Selling and marketing expenses - 1.39M 19.90M - -
Gross profit 0.18M 0.12M 0.12M 0.35M -
Reconciled depreciation 0.30M 0.31M 0.32M 0.33M 0.30M
Ebit -49.70M -44.47M -165.74M -159.65M -107.23M
Ebitda -49.41M -44.16M -165.42M -157.54M -106.94M
Depreciation and amortization 0.30M 0.31M 0.32M 2.10M 0.30M
Non operating income net other - - - 2.10M 0.04M
Operating income -49.70M -67.25M -171.78M -159.65M -106.94M
Other operating expenses 50.35M 69.51M 173.16M 160.02M 106.94M
Interest expense 16.98M 15.13M 13.31M 8.21M 0.04M
Interest income 1.07M 2.60M 6.19M 2.53M 0.04M
Net interest income -15.92M -12.53M -6.61M -5.68M 0.00M
Income tax expense - - 0.15M 6.09M -0.30M
Total revenue 0.64M 2.27M 1.38M 0.38M 0.00M
Total operating expenses 49.88M 67.37M 171.90M 160.00M 106.94M
Cost of revenue 0.46M 2.14M 1.26M 0.02M -
Total other income expense net -20.19M 7.65M -7.27M -6.11M 0.00M
Net income from continuing ops -69.90M -59.60M -211.60M -165.76M -106.93M
Net income applicable to common shares - - - -165.76M -106.93M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 44.92M 38.34M 73.70M 205.85M 239.44M
Other current assets 15.31M 6.73M 4.86M 3.84M 0.96M
Total liab 140.38M 131.44M 130.21M 129.08M 17.77M
Total stockholder equity -95.46M -93.10M -56.51M 76.78M 221.67M
Deferred long term liab - - - 2.34M -
Other current liab 14.29M 5.78M 13.15M 22.35M 11.70M
Common stock 0.08M 0.05M 0.03M 0.03M 0.03M
Capital stock 0.08M 0.05M 0.03M 0.03M 0.03M
Retained earnings -720.09M -650.20M -590.60M -411.55M -245.79M
Other liab - - - 2.34M -
Other assets - - 0.00M 0.93M 0.09M
Cash 28.41M 29.85M 65.22M 193.72M 232.97M
Total current liabilities 53.93M 22.23M 27.27M 32.90M 16.67M
Current deferred revenue - - 0.12M - -
Net debt 81.18M 73.09M 36.16M -99.57M -231.57M
Short term debt 24.93M 0.37M 0.35M 0.32M 0.29M
Short long term debt 24.93M - - - -
Short long term debt total 109.59M 102.95M 101.38M 94.16M 1.40M
Other stockholder equity 624.55M 557.05M 534.06M 488.29M 467.43M
Property plant equipment - - - 1.08M 1.29M
Total current assets 44.69M 37.39M 72.14M 202.87M 232.97M
Net tangible assets - - - 76.78M 221.67M
Net receivables 0.23M 0.13M 0.07M 0.25M -
Long term debt 84.66M 102.51M 100.60M 93.05M -
Inventory 0.72M 0.68M 1.99M 1.99M -
Accounts payable 14.70M 15.99M 13.65M 10.23M 4.68M
Common stock total equity - - - 0.03M 0.03M
Retained earnings total equity - - - -411.55M -245.79M
Non currrent assets other - 0.09M 0.09M 0.93M 3.93M
Non current assets total 0.23M 0.94M 1.56M 2.98M 6.47M
Capital lease obligations 0.07M 0.44M 0.79M 1.10M 1.40M
Long term debt total - - - 93.05M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - 0.00M -0.02M -0.14M -0.45M
Change to liabilities - - - 16.83M 4.85M
Total cashflows from investing activities - - -0.02M -0.14M -0.45M
Net borrowings 0.00M -2.50M 0.00M 95.95M 98.60M
Total cash from financing activities 56.52M 36.66M 26.52M 96.24M 102.45M
Change to operating activities - - - 0.68M 0.13M
Net income -69.90M -59.60M -179.05M -165.76M -106.93M
Change in cash -1.10M -35.37M -128.50M -39.24M 19.85M
Begin period cash flow 29.85M 65.22M 193.72M 232.97M 213.12M
End period cash flow 28.76M 29.85M 65.22M 193.72M 232.97M
Total cash from operating activities -57.62M -72.03M -155.01M -135.34M -82.15M
Issuance of capital stock 58.14M 39.69M 24.66M 0.00M 100.99M
Depreciation 0.30M 0.31M 0.32M 0.33M 0.30M
Change to inventory -0.04M 1.31M -0.01M -1.99M -1.99M
Change to account receivables -0.10M -0.06M 0.18M -0.25M -0.25M
Sale purchase of stock - - -0.03M 0.28M 102.45M
Other cashflows from financing activities -0.02M -0.53M -0.51M 96.24M 1.45M
Change to netincome - - - 18.55M 19.50M
Capital expenditures 0.00M 0.00M 0.02M 0.14M 0.45M
Change receivables - - - -0.25M -
Cash flows other operating - - - -3.93M 0.13M
Cash and cash equivalents changes - - - -39.24M 19.85M
Change in working capital -1.70M -6.03M 2.02M 10.67M 4.98M
Stock based compensation 2.77M 6.16M 18.61M 17.34M 19.45M
Other non cash items 10.92M -12.86M 3.10M 2.08M 0.05M
Free cash flow -57.62M -72.03M -155.03M -135.48M -82.60M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
MKKGY
Merck KGaA ADR		 -0.22
0.66%		 33.17 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 -2.76
1.62%		 167.12 24.86 15.11 3.13 1.98 3.08 18.89
TAK
Takeda Pharmaceutical Co Ltd ADR		 -0.17
0.80%		 21.02 - 10.96 0.01 1.20 2.94 23.11
TKPHF
Takeda Pharmaceutical Co. Ltd.		 -
-%		 41.85 - 10.66 0.01 1.16 2.94 23.11

Profile*

BioXcel Therapeutics Inc

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

555 Long Wharf Drive, New Haven, CT, United States, 06511

475 238 6837

https://www.bioxceltherapeutics.com

29

Name Title Year Born
Dr. Vimal D. Mehta Ph.D. Founder, CEO, Pres, & Director 1961
Dr. Frank D. Yocca Ph.D. Sr. VP & Chief Scientific Officer 1956
Mr. Javier Rodriguez Sr. VP, Chief Legal Officer & Corp. Sec. 1972
Dr. Krishnan Nandabalan Ph.D. Chief Digital Officer ?& Director 1963
Mr. Richard I. Steinhart MBA Sr. VP & CFO 1957
Ms. Mary Coleman VP of Investment Relations NA
Dr. Iris Francesconi Ph.D. Sr. VP of Marketing, Market Research & Commercial Assessments NA
Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P. Sr. VP & Chief Medical Officer 1969
Dr. Cedric Burg VP and Head of Global Clinical Operations & Project Management NA
Dr. Chetan D. Lathia Ph.D. Sr. VP and Head of Translational Medicine, Clinical Pharmacology & Regulatory Affairs NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…